Sensing Drugged Driving: Diagnostic anSERS receives SBIR for roadside drug test

July 20th 2015 – for immediate release • Further information: Sean Virgile, (301) 886-0280 x1021 Read the release at PRWeb • PDF Version Sensing Drugged Driving: Diagnostic anSERS receives SBIR for roadside drug test Diagnostic anSERS Inc. has been awarded a $150,000 grant by the National Science Foundation to develop a paper-based test for identifying drugged drivers, building on their low-cost yet highly sensitive and reliable P-SERS™ testing platform. College Park, MD – Diagnostic anSERS announced today that the National Science Foundation (NSF) has awarded the company a Small Business Innovation Research (SBIR) Phase I grant to identify drugged drivers. With the $150,000 funding, Diagnostic anSERS will develop a paper-based test strip to enable rapid roadside screening for driver drug impairment, a particularly pressing need.  A recent report by the National Highway Traffic Safety Administration found that 13.6% of weekend nighttime drivers tested positive for illegal drugs, as compared to only 1.5% being drunk (NHTSA 2013-2014 National Roadside Survey). At present, no effective roadside drug intoxication test exists. Currently, most states employ Drug Recognition Experts (DREs) to combat drugged drivers. DREs are law enforcement officers specifically trained to identify a variety of signs indicative of drug use, such as coordination and pupil size. However, sobriety exams are time consuming. This, combined with the rising incidence of drug use, means that DREs simply cannot keep up. Compounding this problem is the high cost of keeping a DRE on staff, which severely limits law enforcement’s ability to keep drugged drivers off the roads. “We have interviewed numerous law enforcement officials about their needs, and this was, by far, the biggest and most urgent one. Right now, officers have to either rely on highly trained, highly paid Drug Recognition Experts or let the suspect go. There is no existing cost-effective solution,” said Sean Virgile, co-founder of Diagnostic anSERS. With the societal shift toward decriminalization of marijuana, this problem is only expected to grow. Drivers who have consumed illicit drugs are more likely to be involved in a fatal accident. Drugged driving triples the chance for an accident. Drivers who consume a combination of alcohol and an illegal drug have an incredible 23 times higher risk of crashing.  (NHTSA, Drug and Alcohol Crash Risk, 2015) Diagnostic anSERS’s innovative ink-jet printed P-SERS™ sensors enable the trace detection of a wide variety of chemicals, including narcotics, pesticides, and explosives. This Phase I SBIR, titled Low-cost sensors for rapid narcotic intoxication screening in the field, supports the development of modified P-SERS™ sensors to detect traces of drugs in saliva. This new saliva test will allow a police officer to more accurately determine if a driver is currently under the influence of illegal drug, as opposed to existing...

Read More

P-SERS™ for Cancer Biomarker Detection featured in American Pharmaceutical Review

P-SERS™ for Cancer Biomarker Detection featured in American Pharmaceutical Review

P-SERS™ substrates have been featured in an article published in the American Pharmaceutical Review entitled Raman Spectroscopy Could Facilitate Deployment of Amantadine-Based Cancer Screening Technology – Enabling the Transition from Labs to Villages”. Our partners at Innovative Photonic Solutions and BioMark Diagnostics describe how the combination of functionalized P-SERS™ substrates with reader hardware from IPS has the potential to revolutionize BioMark’s early stage cancer screening test. Currently an expensive central lab test which costs hundreds of dollars, P-SERS™ has the potential to enable cancer screening to be performed in clinics in first and third-world countries for a tiny fraction of the cost of a central-lab test. In partnership with BioMark Diagnostics, research efforts are currently underway at Diagnostic anSERS to develop a proof-of-concept functionalized P-SERS™ sensor to enable low-cost lung cancer screening. The underlying cancer screening test has been in development for nearly a decade and is currently undergoing clinical trials involving hundreds of...

Read More

Sponsor of $135,000 MIPS academic research partnership grant

Diagnostic anSERS Inc. has been awarded a grant through the Maryland Industrial Partnership (MIPS) program, through which $135,000 will go to Dr. Ian White (associate professor, Fischell Department of Bioengineering at the University of Maryland) to help create a field optimized narcotics sensor based on P-SERS™ technology for use in law...

Read More

P-SERS™ at SciX 2014

Attending SciX 2014 from September 28 – October 3 2014? We will be showing off a SERS biomarker detection demo with our spectroscopy partners at Innovative Photonic Solutions! Stop by the IPS booth for an in-depth look at P-SERS™ and to discuss how P-SERS™ and IPS equipment can be combined to create a complete solution to meet your SERS and Raman spectroscopy...

Read More